fxstreet.com 17 Feb, 2021 17:00 am

Senseonics Holdings Inc shares turn south the broad markets, but remains elevated

Senseonics Holdings Inc shares turn south the broad markets, but remains elevated
NYSEAMERICAN:SENS finished the week off strong on Friday as the Maryland-based med-tech company extends its bullish run in 2021. During the final trad

Senseonics investors continue to await FDA approval for its continuous glucose monitoring device.An FDA approval for its glucose monitoring device is critical for the firm's fortunes.SENS shares have been strong of late as investors await information on FDA approval for its diabetes monitoring product.One of the main reasons that Senseonics has been a popular penny stock amongst traders is the impending FDA approval of its continuous glucose monitoring system.

Senseonics has already announced that it expects to receive FDA approval for the Eversense CGM system by the second quarter of 2021, which accounts for much of the stock’s recent success.37 and that in the last 52 weeks, it was a penny stock – trading under $1.

Read full story at fxstreet.com